C16orf45 Activators
Forskolin and IBMX, for example, elevate cAMP levels, subsequently activating PKA, which may phosphorylate proteins associated with C16orf45, altering its activity. Epidermal Growth Factor (EGF) binds to its receptor leading to the activation of MAPK/ERK pathway, while Phorbol 12-myristate 13-acetate (PMA) activates PKC, both of which can modulate gene expression and potentially impact C16orf45 protein levels or activity. Additionally, inhibitors like LY294002 and PD98059, which target PI3K and MEK respectively, can lead to compensatory cellular responses, potentially affecting the activation state of C16orf45. Trichostatin A and 5-Azacytidine influence epigenetic marks, which can alter the expression of a wide array of genes, including those associated with C16orf45. SB431542 disrupts TGF-β signaling, potentially influencing cellular pathways that regulate C16orf45.
Moreover, Wnt pathway modifiers such as Wnt-3a and LiCl, which inhibit GSK-3, can instigate a cascade of events that may involve the activation of genes related to C16orf45 function. Rapamycin, as an mTOR inhibitor, influences cellular growth and metabolism, which could affect the signaling events involving C16orf45. This collection of activators does not engage C16orf45 by direct interaction but instead by influencing the broader cellular context in which the protein operates. The interactions between these chemicals and cellular signaling pathways underscore the complex regulatory networks that govern protein activity, including that of C16orf45.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases (PDEs) which increases cAMP by preventing its breakdown. This elevation in cAMP can result in the activation of PKA, potentially influencing the phosphorylation state of proteins like C16orf45. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC), which can modulate many cellular processes, including those that may upregulate C16orf45 activity or expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K. PI3K inhibition can lead to altered signaling downstream, which can affect the pathways in which C16orf45 is involved, potentially leading to its activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. Inhibition at this point can lead to compensatory cellular responses that may include the activation of alternate pathways involving C16orf45. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. By changing the acetylation status of histones, it can alter gene expression patterns, which can lead to the upregulation of proteins involved in the same pathways as C16orf45. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor, which can lead to demethylation and activation of gene expression. This process can increase the expression of proteins in the same network as C16orf45. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the TGF-β receptor. Inhibition of TGF-β signaling can lead to changes in cellular signaling pathways, possibly affecting those that regulate the activity of C16orf45. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits GSK-3, a kinase involved in Wnt signaling. Inhibition of GSK-3 can lead to the activation of Wnt signaling, which could have downstream effects on the pathways involving C16orf45. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can impact cellular growth and metabolism. This inhibition can trigger a cascade of signaling events that may involve the activation of C16orf45. | ||||||